Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;2(6):333-337.
doi: 10.4021/gr2009.12.1326. Epub 2009 Nov 20.

The Value of Survivin Gene and Proliferation of Hepatocytes in Screening for Hepatocellular Carcinoma

Ke Dong Jia  1 , Zheng Yu Zou  1 , Ding Ying Lv  1
Affiliations

The Value of Survivin Gene and Proliferation of Hepatocytes in Screening for Hepatocellular Carcinoma

Ke Dong Jia et al. Gastroenterology Res. 2009 Dec.

Abstract

Background: The prospective surveillance programs on patients with liver diseases based on repeat ultrasound examinations of liver and serum α-fetoprotein (AFP) detection were reported having the probability of finding hepatocellular carcinoma (HCC) at its early stage, but it is time-consuming and not cost-effective. To improve the effectiveness and cost-effective of HCC surveillance program, close monitoring has been focused on patients with liver cirrhosis who have particularly high risk of HCC development. It has been found that high liver cell proliferation is a reliable predictor of HCC development, and survivin is a new gene with the role of suppressing apoptosis which has been studied mostly over the past few years. This study aimed to evaluate the usefulness of proliferation cell nuclear antigen (PCNA) and survivin detection in the process of screening cirrhotic patients with high risk of HCC development.

Methods: Total RNA was extracted from fresh specimens of HCC and liver cirrhosis. Survivin mRNA amplification was performed by reverse transcription polymerase chain reaction (RT-PCR). Immunostaining for PCNA was employed to assess liver cell proliferation activity in formalin-fixed, paraffin embedded liver specimens. Five liver specimens obtained from patients operated for hemangioma were used as normal control. The PCNA labeling index was determined as the mean value of positive cells in ten different microscopic fields.

Results: RT-PCR was performed in 17 HCC and 10 liver cirrhosis specimens, 11 HCC specimens showed 344bps molecular survivin DNA band in 1% agarose electrophoresis, but none of liver cirrhosis specimens showed positive band. The survivin positive rate in HCC specimens was 64.7% (11/17); The PCNA labeling index was 2.38 ± 2.11 in 30 liver cirrhosis specimens, while 10.08 ± 12.28 in 30 HCC specimens, the latter was significantly higher than the former, P = 0.003. The median PCNA labeling index of 11 survivin positive HCC specimens was 6.8 (from 0.5 to 40), which is significantly higher than that of 6 survivin negative HCC specimens (2.15).

Conclusions: Survivin expressed in HCC tissues but not in liver cirrhosis tissues, this phenomenon indicates that the gene expression may occur at the late phase of liver cell cancer transformation. Compared with survivin detection, the PCNA detection on liver cells of cirrhosis patients is better to differentiate high-risk HCC transformation among liver cirrhosis patients.

Keywords: Hepatocellular carcinoma; Liver cirrhosis; Proliferation; Proliferation cell nuclear antigen; Survivin gene.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The result of Survivin expression (RT-PCR). 1, 6: Normal liver tissue (control); 2, 3: Liver cirrhosis tissue; 4, 5: HCC tissue; M: DNA marker.
See this image and copyright information in PMC

References

    1. Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB, Zhang QH. et al. The natural history of chronic hepatitis B: a retrospective study. Hepatobiliary Pancreat Dis Int. 2003;2(4):566–570. - PubMed
    1. Miyazawa K, Moriyama M, Mikuni M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Kaneko M, Shioda A, Tanaka N, Arakawa Y. Analysis of background factors and evaluation of a population at high risk of hepatocellular carcinoma. Intervirology. 2003;46:150–156. - PubMed
    1. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F. et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48(2):251–259. doi: 10.1136/gut.48.2.251. - DOI - PMC - PubMed
    1. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology. 2000;31(2):330–335. doi: 10.1002/hep.510310211. - DOI - PubMed
    1. Henrion J, Libon E, De Maeght S, Deltenre P, Schapira M, Ghilain JM, Maisin JM, Heller FR. Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin. Gastroenterol Clin Biol. 2003;27:534–539. - PubMed

LinkOut - more resources